Viral Vector– tag –
-
APAC’s Biomanufacturing Ascent: Australia Pioneers Viral Vector Production for Gene Therapies
Industry Publication Australia Overview The Asia-Pacific (APAC) region is rapidly accelerating its specialized manufacturing capabilities for high-value modalities like viral vectors and cell therapies, moving beyond traditional API prod... -
Gene Therapy’s Production Puzzle: Why AAV Outscales Lentiviral Vectors in Large-Scale Manufacturing
Industry Analysis USA Overview A recent analysis comparing AAV and lentiviral vector manufacturing platforms, both produced via transient transfection of HEK293 cells, reveals critical downstream manufacturing distinctions. AAV's stable ... -
Gene Therapy Manufacturing: Viral Vector CDMOs Confront Oversupply Amidst Rapid Expansion
IntuitionLabs USA Overview A recent industry report offers a comparative analysis of the AAV and lentiviral vector CDMO market, revealing trends of consolidation and emerging capacity oversupply. It highlights key players like FUJIFILM D... -
Leading CDMOs Lonza, Samsung Biologics, Charles River Laboratories Spearhead Viral Vector Production, Legend Biotech Drives CAR-T Commercialization
GENE ONLINE|News & Opinion. Blog USA Overview Lonza, Samsung Biologics, and Charles River Laboratories are leading the complex viral vector manufacturing essential for scaling cell and gene therapies (CGTs), while Legend Biotech is drivi... -
Micron Biomedical Secures Microneedle Contract, AbbVie’s Maviret Gains EU Approval, and Moderna’s mRNA Pipeline Advances: Diverse Drug Delivery and Discovery Progress
Drug Discovery News USA Overview The drug discovery and delivery landscape sees diverse advancements: Micron Biomedical secured a $4.5 million NIAID contract for a microneedle patch for radiation injury, highlighting advancements in pain... -
AlphaFold2’s Protein Structure Prediction Breakthrough Earns Nobel Prize, Igniting New Era in AI-Driven Drug Discovery
Facebook (Singularity University) UK Overview Google DeepMind's AlphaFold achieved a groundbreaking advance in protein structure prediction in 2020, leading to a Nobel Prize in 2024 for David Baker, Demis Hassabis, and John Jumper. This ... -
Asia-Pacific Revolutionizes Pharma Manufacturing: Surging Capabilities in HPAPIs, Biologics, and Advanced Therapies
BioProcess International Asia-Pacific Overview The Asia-Pacific (APAC) region is rapidly expanding its specialized pharmaceutical manufacturing capabilities beyond traditional APIs, focusing on high-value modalities like HPAPIs, ADCs, mR... -
AAV Vector Manufacturing Achieves Kilo-Scale Production with 2,000L+ Suspension Bioreactors, Solving Gene Therapy Bottleneck
Drug Discovery News USA Overview AAV upstream production has achieved significant scalability, with suspension bioreactors reaching over 2,000 liters using adapted HEK293 cells, providing volumetric capacity for clinical and commercial g... -
Viral Vector CDMO Capacity Exceeds Clinical Demand: Catalent and Lonza Lead AAV Manufacturing Expansion
IntuitionLabs USA Overview An August 2026 analyst report reveals that viral vector manufacturing capacity, especially for AAV, has outpaced current clinical demand, offering gene therapy sponsors more options and competitive lead times. ... -
Porton Advanced Secures China NMPA Commercial Manufacturing License for CGT Products, Expanding CDMO Services from Process Development to Commercialization
Contract Pharma China Overview Porton Advanced has obtained a Class C drug manufacturing license from China's National Medical Products Administration (NMPA), enabling it to provide commercial contract manufacturing services for cell and...
